touchTALKS Recent advances in neuroimaging technologies and future directions for early assessment and monitoring in Alzheimer’s disease
Watch behavioural neurologist and neuroscientist Dr Brad Dickerson discuss recent advances and future directions in neuroimaging technologies in Alzheimer’s disease.
How can neuroimaging modalities help with early and accurate diagnosis of Alzheimer’s disease?
Dr Brad Dickerson discusses the rationale for early diagnosis, including the impact of potential disease-modifying therapy on clinical practice in patients with early Alzheimer’s disease and an overview of neuroimaging technology and guidelines for diagnostic criteria.
view bio and disclosures 1/3 Next ChapterWhat are the recent advances in neuroimaging technologies and how can they be implemented in practice?
Dr Brad Dickerson provides an overview of PET and MRI technologies and their potential use in Alzheimer’s disease, including practical implementation in imaging centres and the future role of neuroimaging in Alzheimer’s disease.
view bio and disclosures 2/3 Next ChapterWhat is the role of neuroimaging biomarkers for patient diagnosis, selection and monitoring in Alzheimer’s disease?
Dr Brad Dickerson discusses the potential application of neuroimaging biomarkers for precision medicine approaches in Alzheimer’s disease in the context of the current clinical trials, including Aβ PET imaging for preclinical diagnosis and the role in monitoring of amyloid-related imaging abnormalities.
view bio and disclosures 3/3 Take CE/CME TestOverview & Learning Objectives
Overview
In this activity, behavioural neurologist and neuroscientist Dr Brad Dickerson discusses recent advances in neuroimaging technologies and future directions for early assessment and monitoring in Alzheimer’s disease.
This activity has been jointly provided by Oakstone and touchIME NEUROLOGY. Oakstone Publishing is accredited by the ACCME to provide continuing medical education to physicians. read more
Target Audience
This activity has been designed to meet the educational needs of neurologists and radiologists involved in the management of Alzheimer’s disease.
Disclosures
Oakstone Publishing has assessed conflict of interest with its faculty, authors, editors, and any individuals who were in a position to control the content of this CME activity. Any identified relevant conflicts of interest have been mitigated. Oakstone Publishing’s planners, content reviewers, and editorial staff disclose no relationships with ineligible entities.
Faculty
Dr Brad Dickerson discloses: Consulting fees from Acadia, Alector, Arkuda, Axovant, Biogen, Eisai, Life Molecular Sciences, Lilly, Merck, Novartis and Wave Life Sciences. Editorial duties at Elsevier (Neuroimage: Clinical and Cortex). Research support from Alzheimer’s Drug Discovery Foundation and National Institutes of Health. Royalties from Cambridge University Press and Oxford University Press.
Content reviewer
Walter Murray Yarbrough, MD, FACP has no financial interests/relationships or affiliations in relation to this activity.
Touch Medical Director
Sola Neunie has no financial interests/relationships or affiliations in relation to this activity.
Requirements for Successful Completion
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Oakstone Publishing and touchIME. Oakstone Publishing is accredited by the ACCME to provide continuing medical education for physicians.
The European Union of Medical Specialists (UEMS) – European Accreditation Council for Continuing Medical Education (EACCME) has an agreement of mutual recognition of continuing medical education (CME) credit with the American Medical Association (AMA). European physicians interested in converting AMA PRA Category 1 Credit™ into European CME credit (ECMEC) should contact the UEMS (www.uems.eu).
Oakstone Publishing designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
In order to receive credit for this activity, participants must review and complete the post-test and evaluation form. Statements of credit are awarded upon successful completion of the post-test and evaluation form.
Date of original release: 07 June 2021. Date credits expire: 07 June 2022.
Learning Objectives
After watching this activity, participants should be better able to:
- Recognize the importance of early and accurate diagnosis in AD and consider evidence-based guidelines supporting the use of neuroimaging techniques to confirm the diagnosis
- Review recent advances in neuroimaging techniques and their practical application in the current and future management of AD
- Discuss the use of neuroimaging biomarkers for patient diagnosis, selection and monitoring in clinical trials and in the future management of AD
7247
About Dr Brad Dickerson
Dr Brad Dickerson
Harvard Medical School, Boston, MA, USA
Brad Dickerson is a behavioural neurologist and neuroscientist dedicated to the sophisticated, compassionate and multidisciplinary care of patients with neurodegenerative disorders, including Alzheimer’s disease and frontotemporal dementia. He is Director of the MGH Frontotemporal Disorders Unit, Tommy Rickles Endowed Chair in Progressive Aphasia Research, Director of the Neuroimaging Core of the MGH Alzheimer’s Disease Research Center, and a Professor of Neurology at Harvard Medical School. read more
Dr Dickerson runs a large, multidisciplinary team of more than 25 clinicians and scientists using advanced brain imaging and behavioural methods to study how memory, language, emotion and social behaviours change in normal aging and in patients with neurodegenerative disease, with active funding from the National Institutes of Health.
He has published more than 200 articles in peer-reviewed scientific journals as well as many book chapters, and has edited two books on dementia. He is active in mentoring trainees and in teaching, including co-directing the annual Harvard Dementia Course. He is Chair of the Medical and Scientific Advisory Council of the Massachusetts Alzheimer’s Association and is Chair-Elect of the national Medical Advisory Council of the Association for FTD. He has won a number of awards, including the American Academy of Neurology’s Norman Geschwind Award in Behavioral Neurology.
Dr Brad Dickerson discloses: Consulting fees from Acadia, Alector, Arkuda, Axovant, Biogen, Eisai, Life Molecular Sciences, Lilly, Merck, Novartis and Wave Life Sciences. Editorial duties at Elsevier (Neuroimage: Clinical and Cortex). Research support from Alzheimer’s Drug Discovery Foundation and National Institutes of Health. Royalties from Cambridge University Press and Oxford University Press.
Register to touchNEUROLOGY for FREE
- Peer-reviewed journals and expert opinions.
- Interactive CME and e-learning modules.
- Video conference highlights.
